Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Pinometostat

Alternative Names: pinometostat, epz-5676
Latest Update: 2024-06-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DOT1L Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ipsen
Company Location: BOULOGNE BILLANCOURT CEDEX I0 92650
Company CEO: David Loew
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Myeloid Leukemia

Phase 1: Acute Lymphoid Leukemia|Preleukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myeloproliferative Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCI-2018-02349

P2

Terminated

Acute Myeloid Leukemia

2022-11-14

NCI-2018-02128

P2

Completed

Acute Myeloid Leukemia

2020-12-08

EPZ-5676-12-002

P1

Completed

Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2016-05-01

34%
EPZ-5676-12-001

P1

Completed

Acute Myeloid Leukemia|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Myeloproliferative Disorders|Myelodysplastic Syndrome

2015-11-01

34%

Recent News Events

Date

Type

Title

05/01/2024

PubMed

 Loss of RNA-binding protein CELF2 promotes acute leukemia development via FAT10-mTORC1.

04/04/2024

PubMed

 EZH2 as a major histone methyltransferase in PDGF-BB-activated orbital fibroblast in the pathogenesis of Graves' ophthalmopathy.

01/02/2024

PubMed

 Combined small-molecule treatment accelerates maturation of human pluripotent stem cell-derived neurons.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions